Mohammad Faizan Zahid
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mohammad Faizan Zahid has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
Arshalooz Jamila Rahman
3 shared publicationsMoaz Aslam
A Medical College , Aga Khan University , Karachi , Pakistan
3 shared publicationsMohammad Asim Beg
Department of Pathology & Laboratory Medicine, Aga Khan University, Karachi, Pakistan
3 shared publicationsNatasha Ali
Department of Pathology & Laboratory Medicine, Aga Khan University, Karachi, Pakistan; Department of Oncology, Aga Khan University, Karachi, Pakistan
3 shared publicationsMuhammad Asad Maqbool
Medical College, Aga Khan University, Karachi, Pakistan
2 shared publicationsMuhammad Hamza Saad Shaukat
Medical Graduate, Aga Khan University, Karachi, Pakistan
2 shared publications
Latest Publications
- Open Access
- 16 August 2023
- Published by Wiley in European Journal of Haematology
- Vol. 111 (6) , 844-850
Identifying patients at risk for hereditary myeloid malignancy syndromes incorporating a novel, self‐administered questionnaire to an initial screening platform
Introduction: Four to 10% of cases of myeloid malignancies are inherited. We report our experience on hereditary myeloid malignancy syndromes (HMMS) incorporating a novel questionnaire in the screening platform for patients with myeloid malignancies and aplastic anemia.Methods: The questionnaire was sent via electronic patient portal prior to clinic visits. Patients screened positive based on responses to questionnaire items, presence of suspicion disease characteristics (young age, family history, monosomy 7 etc.) and/or presence of signs of HMMS. Those deemed at‐risk based on questionnaire responses, clinical features and/or somatic mutation profile were offered germline testing.Results: A total of 408 patients were screened, 141 (35%) were deemed at‐risk. Fifty‐four (38%) of at‐risk patients were seen in the genetics clinic. Forty‐one (76%) of the patients seen agreed to germline testing and 13 declined due to cost or personal decision. Twenty pathogenic (P)/likely‐pathogenic (LP) germline mutations were identified in 16 (39%) of the tested patients. Five patients also had a variant of uncertain significance (VUS) and an additional 13 had at least 1 VUS without P/LP mutations (total 29 VUS's were found in 18 (44%) of tested patients). The median age of diagnosis for patients with P/LP mutations was 56 years versus 66 years in the entire cohort.Conclusion: Incorporating an electronic questionnaire is an effective screening method for HMMS. Many patients declined testing due to cost. These results highlight the importance of germline testing in patients with myeloid malignancies, further research in HMMS, and coverage by healthcare plans.
- 16 August 2023
- Published by Wiley in European Journal of Haematology
- Vol. 111 (6) , 844-850
Open AccessIdentifying patients at risk for hereditary myeloid malignancy syndromes incorporating a novel, self‐administered questionnaire to an initial screening platform
Introduction: Four to 10% of cases of myeloid malignancies are inherited. We report our experience on hereditary myeloid malignancy syndromes (HMMS) incorporating a novel questionnaire in the screening platform for patients with myeloid malignancies and aplastic anemia.Methods: The questionnaire was sent via electronic patient portal prior to clinic visits. Patients screened positive based on responses to questionnaire items, presence of suspicion disease characteristics (young age, family history, monosomy 7 etc.) and/or presence of signs of HMMS. Those deemed at‐risk based on questionnaire responses, clinical features and/or somatic mutation profile were offered germline testing.Results: A total of 408 patients were screened, 141 (35%) were deemed at‐risk. Fifty‐four (38%) of at‐risk patients were seen in the genetics clinic. Forty‐one (76%) of the patients seen agreed to germline testing and 13 declined due to cost or personal decision. Twenty pathogenic (P)/likely‐pathogenic (LP) germline mutations were identified in 16 (39%) of the tested patients. Five patients also had a variant of uncertain significance (VUS) and an additional 13 had at least 1 VUS without P/LP mutations (total 29 VUS's were found in 18 (44%) of tested patients). The median age of diagnosis for patients with P/LP mutations was 56 years versus 66 years in the entire cohort.Conclusion: Incorporating an electronic questionnaire is an effective screening method for HMMS. Many patients declined testing due to cost. These results highlight the importance of germline testing in patients with myeloid malignancies, further research in HMMS, and coverage by healthcare plans.
- Open Access
- 1 September 2020
- Published by Medknow in Hematology/Oncology and Stem Cell Therapy
- Vol. 13 (3) , 168-170
Sorafenib-induced tumor lysis syndrome in a patient with metastatic hepatocellular carcinoma
Tumor lysis syndrome is a potentially lethal complication of chemotherapy, usually associated with aggressive hematologic malignancies. We describe the case of a young patient with metastatic hepatocellular cancer who developed rapid and fatal tumor lysis syndrome following initiation of sorafenib therapy. Although rare with sorafenib therapy for hepatocellular carcinoma, tumor lysis syndrome is serious complication. Patients with a high burden of disease at therapy initiation should have their metabolic parameters measured prior to starting therapy and closely followed for the first 1–2 weeks while being treated.
- 1 September 2020
- Published by Medknow in Hematology/Oncology and Stem Cell Therapy
- Vol. 13 (3) , 168-170
Open AccessSorafenib-induced tumor lysis syndrome in a patient with metastatic hepatocellular carcinoma
Tumor lysis syndrome is a potentially lethal complication of chemotherapy, usually associated with aggressive hematologic malignancies. We describe the case of a young patient with metastatic hepatocellular cancer who developed rapid and fatal tumor lysis syndrome following initiation of sorafenib therapy. Although rare with sorafenib therapy for hepatocellular carcinoma, tumor lysis syndrome is serious complication. Patients with a high burden of disease at therapy initiation should have their metabolic parameters measured prior to starting therapy and closely followed for the first 1–2 weeks while being treated.
- 25 August 2020
- Published by Springer Nature in Advances in Health Sciences Education
- Vol. 26 (2) , 353-367
Physician-scientist or basic scientist? Exploring the nature of clinicians’ research engagement
Theoretical understanding of what motivates clinician researchers has met with some success in launching research careers, but it does not account for professional identification as a factor determining sustained research engagement over the long-term. Deeper understanding of clinicians’ research-related motivation may better foster their sustained research engagement post-training and, by extension, the advancement of medicine and health outcomes. This study used an integrated theoretical framework (Social Cognitive Career Theory and Professional Identity Formation) and appreciative inquiry to explore the interplay of professional identification and research context in shaping post-training research success narratives. To foreground professional identification, 19 research-active clinicians and 17 basic scientists served as interviewees. A multi-institutional, multi-national design was used to explore how contextual factors shape external valuation of research success. The findings suggest that research-active clinicians do not identify as the career scientists implied by the modern physician-scientist construct and the goal of many clinician research-training programs. Their primary identification as care providers shapes their definition of research success around extending their clinical impact; institutional expectations and prevailing healthcare concerns that value this aim facilitate their sustained research engagement. Integrated developmental and organizational interventions adaptive to research context and conducive to a wider range of medical inquiry may better leverage clinicians’ direct involvement in patient care and advance progress toward human health and well-being.
- 25 August 2020
- Published by Springer Nature in Advances in Health Sciences Education
- Vol. 26 (2) , 353-367
Physician-scientist or basic scientist? Exploring the nature of clinicians’ research engagement
Theoretical understanding of what motivates clinician researchers has met with some success in launching research careers, but it does not account for professional identification as a factor determining sustained research engagement over the long-term. Deeper understanding of clinicians’ research-related motivation may better foster their sustained research engagement post-training and, by extension, the advancement of medicine and health outcomes. This study used an integrated theoretical framework (Social Cognitive Career Theory and Professional Identity Formation) and appreciative inquiry to explore the interplay of professional identification and research context in shaping post-training research success narratives. To foreground professional identification, 19 research-active clinicians and 17 basic scientists served as interviewees. A multi-institutional, multi-national design was used to explore how contextual factors shape external valuation of research success. The findings suggest that research-active clinicians do not identify as the career scientists implied by the modern physician-scientist construct and the goal of many clinician research-training programs. Their primary identification as care providers shapes their definition of research success around extending their clinical impact; institutional expectations and prevailing healthcare concerns that value this aim facilitate their sustained research engagement. Integrated developmental and organizational interventions adaptive to research context and conducive to a wider range of medical inquiry may better leverage clinicians’ direct involvement in patient care and advance progress toward human health and well-being.
- Open Access
- 1 October 2019
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 41 (4) , 292-297
Infections in patients with multiple myeloma treated with conventional chemotherapy: a single-center, 10-year experience in Pakistan
- 1 October 2019
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 41 (4) , 292-297
Open AccessInfections in patients with multiple myeloma treated with conventional chemotherapy: a single-center, 10-year experience in Pakistan
- Open Access
- 1 July 2019
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 41 (3) , 275-277
Rapid resolution of prostate cancer-related hemolytic uremic syndrome without plasma exchange – a case report
- 1 July 2019
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 41 (3) , 275-277
Open AccessRapid resolution of prostate cancer-related hemolytic uremic syndrome without plasma exchange – a case report
- 21 September 2018
- Published by Taylor & Francis in Drug and Chemical Toxicology
- Vol. 43 (6) , 588-594
Hepatoprotective and antioxidant activities of Annona squamosa seed extract against alcohol-induced liver injury in Sprague Dawley rats
Alcohol is regarded as the third most common cause of death after hypertension and smoking. Its long-term excess exposure leads to alcoholic liver disease (ALD) and liver injury, a worldwide health problem without efficient therapy. As there is no reliable liver protective drugs in allopathic medical practices, herbs play a major role in the management of liver diseases. Thus, the present study was designed to evaluate hepatoprotective activity of Annona squamosa seed extract against alcohol-induced liver injury in Sprague Dawley rats. Liver toxicity was induced by 50% alcohol at dose level of 12 ml/kg po each, for 8 days. Ethanolic extract of A. squamosa seed (EEAS) at dose of 200 and 400 mg/kg po were administered once daily for 8 consecutive days. The hepatoprotective activity of EEAS was assessed in experimental rats using various biochemical parameters like ALT, AST, ALP, LDH, SBL, albumin, total cholesterol, and total protein; and antioxidant parameters like SOD, CAT, GSH, and TBARS. It demonstrated that the treatment with EEAS significantly (p < 0.05–p < 0.001) and dose-dependently prevented the alcohol-induced increase in serum levels of hepatic enzymes and significantly increased the levels of SOD, CAT, and GSH. It also significantly decreased the level of MDA. Histopathology of the liver tissues showed that EEAS attenuated the hepatocellular necrosis and led to regeneration and repair of cells toward normal. Results of this study strongly indicated the protective effect of A. squamosa against alcohol-induced liver injury which may be attributed to its hepatoprotective and antioxidant activities. Graphical Abstract
- 21 September 2018
- Published by Taylor & Francis in Drug and Chemical Toxicology
- Vol. 43 (6) , 588-594
Hepatoprotective and antioxidant activities of Annona squamosa seed extract against alcohol-induced liver injury in Sprague Dawley rats
Alcohol is regarded as the third most common cause of death after hypertension and smoking. Its long-term excess exposure leads to alcoholic liver disease (ALD) and liver injury, a worldwide health problem without efficient therapy. As there is no reliable liver protective drugs in allopathic medical practices, herbs play a major role in the management of liver diseases. Thus, the present study was designed to evaluate hepatoprotective activity of Annona squamosa seed extract against alcohol-induced liver injury in Sprague Dawley rats. Liver toxicity was induced by 50% alcohol at dose level of 12 ml/kg po each, for 8 days. Ethanolic extract of A. squamosa seed (EEAS) at dose of 200 and 400 mg/kg po were administered once daily for 8 consecutive days. The hepatoprotective activity of EEAS was assessed in experimental rats using various biochemical parameters like ALT, AST, ALP, LDH, SBL, albumin, total cholesterol, and total protein; and antioxidant parameters like SOD, CAT, GSH, and TBARS. It demonstrated that the treatment with EEAS significantly (p < 0.05–p < 0.001) and dose-dependently prevented the alcohol-induced increase in serum levels of hepatic enzymes and significantly increased the levels of SOD, CAT, and GSH. It also significantly decreased the level of MDA. Histopathology of the liver tissues showed that EEAS attenuated the hepatocellular necrosis and led to regeneration and repair of cells toward normal. Results of this study strongly indicated the protective effect of A. squamosa against alcohol-induced liver injury which may be attributed to its hepatoprotective and antioxidant activities. Graphical Abstract
- Open Access
- 24 January 2018
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 35 (3) , 205-206
Spurious thrombocytosis in the setting of hemolytic anemia and microcytosis secondary to extensive burn injury
- 24 January 2018
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 35 (3) , 205-206
Open AccessSpurious thrombocytosis in the setting of hemolytic anemia and microcytosis secondary to extensive burn injury
- Open Access
- 1 July 2017
- Vol. 11 (3) , 231-239
Cytogenetic Abnormalities in Myelodysplastic Syndromes: An Overview
Karyotype is one of the main constituents of the International Prognostic Scoring System (IPSS) and revised-IPSS that are the cornerstones for the prognostication of patients with myelodysplastic syndromes (MDS). Del(5q), –7/del(7q), +8 and –Y are among the most extensively studied cytogenetic abnormalities in MDS. The same applies for normal karyotype. There are hundreds of other rare cytogenetic abnormalities that have been reported in MDS, included but not limited to –X, 3q abnormalities, +13/del(13q), i(17q), +21/–21. However, due to a very low number of patients, their impact on the prognosis of MDS is limited. Knowledge of the molecular consequences of different cytogenetic abnormalities allows us to modify treatment regimens based on drugs most active against the specific karyotype present, allowing for the opportunity to individualize MDS treatment and improve patient care and prognosis.
- 1 July 2017
- Vol. 11 (3) , 231-239
Open AccessCytogenetic Abnormalities in Myelodysplastic Syndromes: An Overview
Karyotype is one of the main constituents of the International Prognostic Scoring System (IPSS) and revised-IPSS that are the cornerstones for the prognostication of patients with myelodysplastic syndromes (MDS). Del(5q), –7/del(7q), +8 and –Y are among the most extensively studied cytogenetic abnormalities in MDS. The same applies for normal karyotype. There are hundreds of other rare cytogenetic abnormalities that have been reported in MDS, included but not limited to –X, 3q abnormalities, +13/del(13q), i(17q), +21/–21. However, due to a very low number of patients, their impact on the prognosis of MDS is limited. Knowledge of the molecular consequences of different cytogenetic abnormalities allows us to modify treatment regimens based on drugs most active against the specific karyotype present, allowing for the opportunity to individualize MDS treatment and improve patient care and prognosis.
- 1 November 2016
- Published by Frontline Medical Communications, Inc. in The Journal of Community and Supportive Oncology
- Vol. 14 (11) , 457-465
Outcome of tumor lysis syndrome in pediatric patients with hematologic malignancies – a single-center experience from Pakistan
- 1 November 2016
- Published by Frontline Medical Communications, Inc. in The Journal of Community and Supportive Oncology
- Vol. 14 (11) , 457-465
Outcome of tumor lysis syndrome in pediatric patients with hematologic malignancies – a single-center experience from Pakistan
- 22 June 2016
- Vol. 28 (1) , 201-3
MUMPS MYOCARDITIS: A FORGOTTEN DISEASE?
Mumps is an acute viral illness that follows a self-limiting course but up to 10% of cases have a complicated course with the involvement of other organ systems. Myocarditis is reported as a complication but the incidence has greatly fallen ever since the development of the mumps vaccine. A child presented to our department with parotid swelling and fever. Persistent tachycardia with irregular pulse led to further cardiac work up which showed decreased ejection fraction and raised serum cardiac enzymes, indicating myocardial damage. With ionotropic agents and supportive care, there was complete normalization of ejection fraction and serum cardiac enzyme levels. He was discharged within a week of admission. This case highlights the importance of suspecting myocarditis in the setting of mumps, a diagnosis that precludes early suspicion in mumps patients suffering from cardiac symptoms not explained by other potential aetiologies. Early suspicion and timely supportive care are essential to ensure favourable outcomes.
- 22 June 2016
- Vol. 28 (1) , 201-3
MUMPS MYOCARDITIS: A FORGOTTEN DISEASE?
Mumps is an acute viral illness that follows a self-limiting course but up to 10% of cases have a complicated course with the involvement of other organ systems. Myocarditis is reported as a complication but the incidence has greatly fallen ever since the development of the mumps vaccine. A child presented to our department with parotid swelling and fever. Persistent tachycardia with irregular pulse led to further cardiac work up which showed decreased ejection fraction and raised serum cardiac enzymes, indicating myocardial damage. With ionotropic agents and supportive care, there was complete normalization of ejection fraction and serum cardiac enzyme levels. He was discharged within a week of admission. This case highlights the importance of suspecting myocarditis in the setting of mumps, a diagnosis that precludes early suspicion in mumps patients suffering from cardiac symptoms not explained by other potential aetiologies. Early suspicion and timely supportive care are essential to ensure favourable outcomes.